<SEC-DOCUMENT>0001062993-17-004034.txt : 20170906
<SEC-HEADER>0001062993-17-004034.hdr.sgml : 20170906
<ACCEPTANCE-DATETIME>20170905181953
ACCESSION NUMBER:		0001062993-17-004034
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170831
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170906
DATE AS OF CHANGE:		20170905

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		171069823

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>August
31, 2017</U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) <BR></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-52138 </U></B></TD>
  <TD align=center width="33%"><B><U>20-2000871 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
  <TD align=center width="33%">(IRS Employer </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=center width="33%">&nbsp; </TD>
  <TD align=center width="33%">Identification No.) </TD>
  </TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="50%" align=center><B><U>156 Valleyview Road, Kelowna, BC Canada </U></B></TD>
  <TD align=center width="50%" ><B><U>V1X 3M4 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD width="50%" align=center>(Address of principal executive offices) </TD>
  <TD align=center width="50%" >(Zip Code) </TD>
  </TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code <B><U>(250)
765-6424</U></B><B> </B></P>
<P align=center><B><U>N/A</U></B><B> </B><BR>(Former name or former address, if
changed since last report.) <BR></P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp; ]&nbsp; Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)<BR>[&nbsp;&nbsp; ]&nbsp;
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)<BR>
[&nbsp;&nbsp; ]&nbsp; Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
[&nbsp;&nbsp;
]&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))<BR>
</P>
<P align=justify>Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b -2
of this chapter). </P>
<P align=right>Emerging growth company [&nbsp;&nbsp; ]&nbsp; </P>
<P align=justify>If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. [&nbsp;&nbsp; ]&nbsp; </P>
<P align=justify><B>Item
7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Regulation FD Disclosure </B></P>
<P align=justify>A copy of the news release announcing the world&#146;s first
clinical study on human volunteers of cannabindiol (CBD) within Lexaria&#146;s high
absorption TurboCBD&#153; product is filed as exhibit 99.1 to this current report and
is hereby incorporated by reference. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Item 9.01</B> </TD>
    <TD align=left width="90%" ><B>Financial Statements and
      Exhibits</B> </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="90%" bgColor=#eeeeee ><a href="exhibit99-1.htm">Press Release
      dated August 31, 2017 </a></TD>
  </TR></TABLE>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR></TABLE>
<P
align=justify>Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;August 31, 2017</P>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right><B>Exhibit 99.1 </B></P>
<P align=center><B>University of British Columbia to Perform Clinical Study on
the Cardiovascular and </B><BR><B>Cognitive Health Effects of Lexaria&#146;s
TurboCBD</B><B><SUP>TM</SUP></B><B>. </B><BR></P>
<P align=justify>Kelowna, British Columbia &#150; August 31, 2017 &#150; Lexaria
Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;) announces
the world&#146;s first clinical study on human volunteers of cannabindiol (CBD)
within Lexaria&#146;s high absorption TurboCBD&#153; product, to evaluate its effects on
both cardiovascular health and cognitive function.</P>
<P align=justify>The study will have a double-blind and placebo controlled
cross-over design measuring effects both after a single dose, and also after 7
days of daily dosing in 24 volunteers. The study hypothesises that, following
TurboCBD&#153; supplementation, circulating CBD and nitric oxide will increase in
both young and old participants; that glucose and blood pressure will remain
stable; and that vascular function, and cognitive and physical exercise
performance will improve to a greater extent in older participants. This
research study has been approved by the Clinical Research Ethics Board at the
University of British Columbia (&#147;UBC&#148;).</P>
<P align=justify>Professor Philip Ainslie, PhD, Co-Director of the Centre for
Heart, Lung and Vascular Health, UBC Okanagan Campus, Kelowna, Canada, will be
Principal Investigator of a team of co-investigators. UBC has consistently been
ranked one of the top three universities in Canada, has over 62,000 students on
two campuses, and is further considered one of the top research universities in
the world. UBC has conducted several earlier studies in the cannabis sector,
available for review at <U><FONT
color=#0000ff>https://news.ubc.ca/tag/marijuana/ </FONT></U></P>
<P align=justify>This advanced study will utilize the latest clinical evaluation
techniques to provide pharma-level pharmacokinetic and pharmacodynamic
performance data of TurboCBD&#153;, including blood sampling, physiological measures,
cognitive function testing, vascular function testing, and exercise performance
testing. Outcome measurements will include circulating CBD and nitric oxide
markers, plasma glucose, plasma insulin, blood pressure, heart rate,
respiration, peripheral and brain blood flow and a battery of neuropsychological
performance tests. </P>
<P align=justify>Dr. Philip Ainslie comments that, &#147;This study gives us a great
opportunity to obtain world class clinical data on the health and performance
benefits of cannabidiol using Lexaria&#146;s unique high absorption TurboCBD&#153;
capsules in our state of the art laboratories. It is very exciting to be one of
the first &#150; if not the first &#150; to conduct these kinds of studies in Canada. The
potential implications of the study are far-reaching: from understanding the
fundamental biological mechanism(s) of high absorption CBD in humans, to how
this might influence blood vessel physiology and human performance. To quantify
the pharmacokinetics of TurboCBD&#153; will allow us to make informed recommendations
of optimum dosing in order to improve vascular health and performance throughout
healthy aging. Once we understand these processes better, the applications to
various clinical populations can then be explored. There are also many other CBD
products from Lexaria that could also be explored in due course &#150; the
partnership with academia and Lexaria Biosciences is an excellent means to
develop new collaborative ideas, products and positively impact society.&#148;</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=justify>&#147;Lexaria is proud to be advancing our collective knowledge of
the benefits of CBD specifically showcasing the benefits of Lexaria&#146;s unique patented delivery
technology,&#148; said Chris Bunka, CEO of Lexaria Bioscience. &#147;Results will advance
Lexaria&#146;s ability to custom design products that increase the leading
performance our technology already offers to customers.&#148;</P>
<P align=justify>Additional information will be released upon completion and
interpretation of test results. </P>
<P align=justify><B>About Lexaria <BR></B>Lexaria Bioscience Corp. has developed
and out-licenses its disruptive technology that promotes healthier ingestion
methods, lower overall dosing and higher effectiveness of lipophilic active
molecules. Lexaria has multiple patents pending in over 40 countries around the
world and was granted its first patents in the USA and in Australia related to
edible forms of cannabinoids. Lexaria&#146;s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. </P>
<P align=justify><U><FONT color=#0000ff>www.lexariabioscience.com
</FONT></U><BR>For regular updates, connect with Lexaria on Facebook (<U><FONT
color=#0000ff>https://www.facebook.com/Lexaria-</FONT></U><BR><U><FONT
color=#0000ff>Corp-106280556370600/</FONT></U>) and Twitter (<U><FONT
color=#0000ff>https://twitter.com/lexariacorp</FONT></U>)<BR></P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>Lexaria Bioscience
Corp.<BR>Alex Blanchard, Communications Manager <BR>(778) 796-1897 <BR>Or
<BR>NetworkNewsWire (NNW) <BR><U><FONT color=#0000ff>www.NetworkNewsWire.com
</FONT></U><BR></P>
<P align=justify>FORWARD-LOOKING STATEMENTS <BR>This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional stock warrants or stock options will be
exercised. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. Factors which could
cause actual results to differ materially from those estimated by the Company
include, but are not limited to, government regulation, managing and maintaining
growth, the effect of adverse publicity, litigation, competition, the patent
application and approval process and other factors which may be identified from
time to time in the Company's public announcements and filings. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will be able to raise additional capital. There is no assurance that Lexaria
will successfully complete any other contemplated or existing technology license
agreements; or that results from any studies will be favorable or in any way
support future business activities of any kind. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any of Lexaria&#146;s
postulated uses, benefits, or advantages for the patented and patent-pending
technology will in fact be realized in any manner or in any part. No statement
herein has been evaluated by the Food and Drug Administration (FDA). Lexaria
Energy Foods, Ambarii, and ViPova<SUP>TM </SUP>products are not intended to
diagnose, treat, cure or prevent any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
